Rekombinanter TIGIT (Tiragolumab Biosimilar) Antikörper
Kurzübersicht für Rekombinanter TIGIT (Tiragolumab Biosimilar) Antikörper (ABIN7581704)
Target
Antikörpertyp
Reaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Expressionssystem
- CHO Cells
-
Verwendungszweck
- Anti-TIGIT Reference Antibody (tiragolumab)
-
Sequenz
- EVQLQQSGPG LVKPSQTLSL TCAISGDSVS SNSAAWNWIR QSPSRGLEWL GKTYYRFKWY SDYAVSVKGR ITINPDTSKN QFSLQLNSVT PEDTAVFYCT RESTTYDLLA GPFDYWGQGT LVTVSSASTK GPSVFPLAPS SKSTSGGTAA LGCLVKDYFP EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS SLGTQTYICN VNHKPSNTKV DKKVEPKSCD KTHTCPPCPA PELLGGPSVF LFPPKPKDTL MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYNSTYR VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVYTL PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPGK,DIVMTQSPDS LAVSLGERAT INCKSSQTVL YSSNNKKYLA WYQQKPGQPP NLLIYWASTR ESGVPDRFSG SGSGTDFTLT ISSLQAEDVA VYYCQQYYST PFTFGPGTKV EIKRTVAAPS VFIFPPSDEQ LKSGTASVVC LLNNFYPREA KVQWKVDNAL QSGNSQESVT EQDSKDSTYS LSSTLTLSKA DYEKHKVYAC EVTHQGLSSP VTKSFNRGEC
-
Produktmerkmale
- Anti-TIGIT Reference Antibody (tiragolumab) is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.
-
Reinheit
- >95 %
-
Isotyp
- IgG1
-
-
-
-
Applikationshinweise
- Optimal working dilution should be determined by the investigator.
-
Kommentare
-
Therapeutic Agents by Target and Mechanism: TIGIT inhibitors
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Lyophilized
-
Konzentration
- 1 mg/mL
-
Buffer
- 25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
-
Lagerung
- 4 °C,-80 °C
-
Informationen zur Lagerung
- +4°C,-80°C
-
-
- TIGIT (Tiragolumab Biosimilar)
-
Substanzklasse
- Biosimilar
-
Molekulargewicht
- 145.5 kDa
-
UniProt
- Q495A1
Target
-